Get the Stockscreener App
67.87
0.54%
-0.37
Grail Inc stock is traded at $67.87, with a volume of 433.08K.
It is down -0.54% in the last 24 hours and down -7.18% over the past month.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
See More
Previous Close:
$68.24
Open:
$67.98
24h Volume:
433.08K
Relative Volume:
0.62
Market Cap:
$3.03B
Revenue:
$156.12M
Net Income/Loss:
$-395.33M
P/E Ratio:
-6.5412
EPS:
-10.3758
Net Cash Flow:
$-292.33M
1W Performance:
-2.32%
1M Performance:
-7.18%
6M Performance:
-30.39%
1Y Performance:
+110.91%
1-Day Range:
$66.35
$68.71
1-Week Range:
$66.35
$76.44
52-Week Range:
$29.95
$118.84
Grail Inc Stock (GRAL) Company Profile
Name
Grail Inc
Sector
Industry
Phone
(833) 694-2553
Address
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, NTRA, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
67.87 | 3.08B | 156.12M | -395.33M | -292.33M | -10.38 |
TMO
Thermo Fisher Scientific Inc
|
588.29 | 222.96B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.45 | 144.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
309.93 | 45.54B | 2.50B | -226.32M | 71.51M | -1.6412 |
IDXX
Idexx Laboratories Inc
|
550.96 | 44.95B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
148.53 | 41.87B | 7.23B | 1.41B | 1.09B | 4.979 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Mizuho | Neutral |
| Mar-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-19-26 | Initiated | TD Cowen | Hold |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-25 | Initiated | Canaccord Genuity | Buy |
| Nov-27-24 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-24 | Initiated | Guggenheim | Neutral |
View All
Grail Inc Stock (GRAL) Latest News
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting - MarketBeat
GRAL|Grail Inc|Price:68.180|Chg%:-0.760 - tradingkey.com
Farallon group discloses 9.6% GRAIL, Inc. (GRAL) holding in Schedule 13G/A - Stock Titan
GRAIL, Inc. (NASDAQ:GRAL) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Bank of America Corp DE Purchases 205,611 Shares of GRAIL, Inc. $GRAL - MarketBeat
GRAIL: Looking Beyond The NHS-Galleri Headline (NASDAQ:GRAL) - Seeking Alpha
GRAIL (NASDAQ:GRAL) Stock Price Down 6.3%What's Next? - MarketBeat
Cancer Detection Firm Nears FDA Breakthrough Blood-Test Review - Streetwise Reports
GRAIL Galleri Test Heads to FDA Panel for Multi-Cancer Screening Review - Streetwise Reports
FDA panel to review GRAIL’s Galleri multi-cancer blood test in September - Mugglehead Investment Magazine
GRAIL (NASDAQ:GRAL) Trading Up 7.6%Time to Buy? - MarketBeat
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test - benzinga.com
FDA panel to weigh Grail’s Galleri test - STAT
GRAIL’s Galleri becomes first multi-cancer detection test headed to US FDA advisory panel - AllSci
Renaissance Technologies LLC Sells 30,100 Shares of GRAIL, Inc. $GRAL - MarketBeat
Illumina Seeks Court Approval of GRAIL Settlement - The Globe and Mail
GRAIL Inc Revenue Breakdown – LSX:A40F8M - TradingView
Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date? - Yahoo Finance
US FDA to hold advisory meeting to review Grail’s multi-cancer test - WTVB
US FDA to hold advisory meeting to review Grail's multi-cancer test - Reuters
FDA to hold adcomm for Grail cancer test that failed in large, randomized trial - Endpoints News
FDA panel to review GRAIL’s cancer detection test on Sept. 23 - Investing.com
GRAIL Insiders Sold US$29m Of Shares Suggesting Hesitancy - Moomoo
GRAIL to face FDA AdCom for Galleri cancer test (GRAL:NASDAQ) - Seeking Alpha
GRAIL Says FDA Advisory Committee To Review GRAIL Galleri PMA Application On September 23 - TradingView
GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test - PR Newswire
Analysts Offer Insights on NA Companies: GRAIL Inc (GRAL) and SanDisk Corp (SNDK) - The Globe and Mail
State Street Corporation (NASDAQ: GRAL) reports 5.6% beneficial stake in GRAIL - Stock Titan
GRAIL Bets Its Galleri Panel Will Set The FDA Bar For Future MCEDs - insights.citeline.com
Dimensional Fund Advisors LP Purchases 191,857 Shares of GRAIL, Inc. $GRAL - MarketBeat
PRIMECAP Management (GRAL) discloses 21.8M-share, 5.08% stake in GRAIL - Stock Titan
GRAIL, Inc. 2026: Revenue $44.69M, EPS ($2.56) — 10-Q Summary - TradingView
[10-Q] GRAIL, Inc. Quarterly Earnings Report - Stock Titan
GRAIL (NASDAQ:GRAL) Shares Down 12.2%What's Next? - MarketBeat
GRAL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
GRAIL, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
GRAL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
GRAIL Inc (GRAL) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
GRAIL INC Q2 NET INCOME USD -110.247 MILLION - Moomoo
GRAIL Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: GRAIL beats revenue in Q2 2026, shares fall after hours - Investing.com
GRAIL (NASDAQ:GRAL) Announces Earnings Results - MarketBeat
GRAIL shares tumble despite revenue beat on Q2 results By Investing.com - Investing.com Nigeria
Grail Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (GRAL) GRAIL, Inc. Reports Q2 Revenue $44.7M, vs. FactSet Est of $42.4M - marketscreener.com
Grail reports Q2 2026 revenue up 26% to $44.7M; net loss $110.2M - TradingView
GRAIL (Nasdaq: GRAL) Q2 revenue rises 26% as net loss narrows - stocktitan.net
Grail Inc Q2 Income From Operations USD -173. - Moomoo
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026 - morningstar.com
GRAL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GRAIL, Inc. Securities LawsuitContact The Gross Law Firm - morningstar.com
GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - morningstar.com
Grail Inc Stock (GRAL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):